Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study (Q24610626)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Feasibility study and methodology to create a quality-evaluated database of primary care data

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Clinical pharmacology of the angiotensin II receptor antagonist losartan potassium in healthy subjects.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Cardiovascular drugs and serum uric acid

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Uric acid: role in cardiovascular disease and effects of losartan

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Role of actions of calcium antagonists on efferent arterioles--with special references to glomerular hypertension

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Omeprazole, other antiulcer drugs and newly diagnosed gout

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

A language of health in action: Read Codes, classifications and groupings.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Renal effects of angiotensin II receptor blockade in normotensive subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

The impact of serum uric acid on cardiovascular outcomes in the LIFE study

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

AT1 blockers and uric acid metabolism: are there relevant differences?

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Read Codes Version 3: a user led terminology.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3257215

Comparative Effects of Ticrynafen and Hydrochlorothiazide in the Treatment of Hypertension

28 November 2018

1 reference

12 December 2020

Serum uric acid in essential hypertension: an indicator of renal vascular involvement

1 reference

12 December 2020

Uric acid in childhood essential hypertension

1 reference

12 December 2020

Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension

1 reference

12 December 2020

Renal uric acid handling is not affected by beta-adrenoceptor blockade in normotensive subjects

1 reference

12 December 2020

Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives

1 reference

12 December 2020

The metabolic effects of enalapril

1 reference

12 December 2020

Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects

1 reference

12 December 2020

The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients

1 reference

12 December 2020

Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension

1 reference

12 December 2020

Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia

1 reference

12 December 2020

Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome

1 reference

12 December 2020

Gout and risk of Parkinson disease: A prospective study

1 reference

12 December 2020

Effect of valsartan on renal handling of uric acid in healthy subjects

1 reference

12 December 2020

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators

1 reference

12 December 2020

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension

1 reference

12 December 2020

release_m7xi2g3w6vd6vp3f3wgja3jvgm

Identifiers

DOI

10.1136/BMJ.D8190

0 references

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m7xi2g3w6vd6vp3f3wgja3jvgm

24 November 2022